<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM21030-54M-RR-2DS"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 S176 IS: Ensuring Understanding of COVID–19 to Protect Public Health Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2021-02-02</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>117th CONGRESS</congress><session>1st Session</session><legis-num>S. 176</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20210202">February 2, 2021</action-date><action-desc><sponsor name-id="S402">Ms. Rosen</sponsor> (for herself and <cosponsor name-id="S350">Mr. Rubio</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To require a longitudinal study on the impact of COVID–19.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="S1"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ensuring Understanding of COVID–19 to Protect Public Health Act</short-title></quote>.</text></section><section id="id78F71078B943484F8CE289200FAFAC35"><enum>2.</enum><header>Study on the impact of COVID–19</header><text display-inline="no-display-inline">Part A of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/281">42 U.S.C. 281</external-xref> et seq.) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="id9B5A958B802A48FD9CB1B5CB5647F02E"><section id="id7D27904D00A74DB9B949AF179BBA7CC4"><enum>404O.</enum><header>Study on the impact of COVID–19</header><subsection id="id8F32FEDEF49E4E1180DCECF8955AF3FA"><enum>(a)</enum><header>In general</header><text>The Director of NIH, in consultation with the Director of the Centers for Disease Control and Prevention, shall conduct a longitudinal study, over not less than 10 years, on the full impact of COVID–19 on infected individuals, including both short-term and long-term health impacts. </text></subsection><subsection id="id0E883954A8A0445A95B0A5A91B8EFB21"><enum>(b)</enum><header>Timing</header><text>The Director of NIH shall begin enrolling patients in the study under this section not later than 6 months after the date of enactment of this section. </text></subsection><subsection id="idFDCE121ECCB546DC8832F6B743F954FE"><enum>(c)</enum><header>Requirements</header><text>The study under this section shall—</text><paragraph id="id81C3FBB312A34B1A80B85217522FA851"><enum>(1)</enum><text>be nationwide;</text></paragraph><paragraph id="idDF4BA940A2254049B819FE126C8DD0C3"><enum>(2)</enum><text>include diversity of enrollees to account for gender, age, race, ethnicity, geography, comorbidities, and underrepresented populations, including pregnant and lactating women;</text></paragraph><paragraph id="idEF6862E851694252AB773E1CE10DD58D"><enum>(3)</enum><text>study individuals who were infected with COVID–19 who experienced mild symptoms, such individuals who experienced moderate symptoms, and such individuals who experienced severe symptoms;</text></paragraph><paragraph id="id7F6880901EEC4EC4ADA1201A76E42799"><enum>(4)</enum><text>monitor the health outcomes and symptoms of individuals who were infected with COVID–19, or had prenatal exposure to COVID–19, including lung capacity and function, and immune response, taking into account any pharmaceutical interventions such individuals may have received; </text></paragraph><paragraph id="id2B9B945C77AC474B8E5BB0B976548D74"><enum>(5)</enum><text>monitor the mental health outcomes of individuals infected with COVID–19, taking into account any interventions that affected mental health; and</text></paragraph><paragraph id="id76416147CEC04AE489BA300DDD2CEF45"><enum>(6)</enum><text>monitor individuals enrolled in the study not less frequently than twice per year after the first year of the individual's infection with COVID–19.</text></paragraph></subsection><subsection id="id6D966B24079749D683E2B42CE499BDFD"><enum>(d)</enum><header>Public-Private research network</header><text>For purposes of carrying out the study under this section, the Director of NIH may develop a network of public-private research partners, provided that all research, including the research carried out through any such partner, is available publicly.</text></subsection><subsection id="id789fad46a7cc4304b6d65d5b350de9f9"><enum>(e)</enum><header>Summaries of findings</header><text>The Director of NIH shall make public a summary of findings under this section not less frequently than once every 3 months for the first 2 years of the study, and not less frequently than every 6 months thereafter. Such summaries may include information about how the findings of the study under this section compare with findings from research conducted abroad.</text></subsection><subsection id="idE965A33C37484F8891DF5603170026FC"><enum>(f)</enum><header>Authorization of appropriations</header><text>There are authorized to be appropriated such sums as may be necessary to carry out this section.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

